Podcasts about division head

How a robot named Gina gave a BC woman her life back Guest: Dr. Timothy Kostamo, Division Head of Orthopedics at Burnaby Hospital Learn more about your ad choices. Visit megaphone.fm/adchoices

Is being a municipal councillor a part-time job? Guest: Tim Baillie, Councillor of Langley Township How a robot named Gina gave a BC woman her life back Guest: Dr. Timothy Kostamo, Division Head of Orthopedics at Burnaby Hospital Will the Nechako be a big river again? Guest: Lyana Patrick, Director of Nechako: It Will Be A Big River Again Why do we forget our childhood memories? Guest: Dr. Sarah Power, Postdoctoral Researcher in the Department of Lifespan Psychology at the Max Planck Institute for Human Development Weekly Cecchini Check-In Guest: Reggie Cecchini, Washington Correspondent for Global News Learn more about your ad choices. Visit megaphone.fm/adchoices

Previously Akiko was a Commentator for Fuji TV; Co-Founder of Women In Action; Partner, Strategy &; Division Head at Japan Post; Vice-President Calyon Securities; Associate McKinsey & Company; Vice-President and Associate, General Counsel J.P. Morgan. She graduated with a JD in Law from Tokyo University and has a Master Of Law from Columbia Law School “Culture is an accumulation of behaviors—what you say and do becomes the culture.” “If the ownership is there, it's really easy to engage with them.” “Listen more than you speak—especially in Japan, silence often hides valuable insight.” “You can't have a single leadership approach—it's person by person.” “Deliver, manage expectations, and be transparent—that's how you build trust.” Akiko's leadership approach is deeply rooted in clarity of direction, respect for individuality, and adaptive engagement. Her philosophy is shaped by diverse experiences in legal, consulting, and advisory roles, and it centres on fostering ownership within her teams. She emphasizes the importance of building a shared vision and selecting people whose strengths and motivations align with that direction. For her, engagement begins with recruiting the right individuals and then shaping an environment that supports their ownership of outcomes. Whether inheriting a team or building one from scratch, she focuses on identifying key issues, defining areas of impact, and matching people to those missions. She acknowledges that leadership today demands flexibility, as people differ in how they want to be led—some thrive with autonomy while others need close collaboration. Her leadership style is not one-size-fits-all; instead, it's adaptive and rooted in an appreciation of diversity—not only in personality but in professional backgrounds. Akiko credits the richness of ideas within her organization to this diversity, noting that innovation emerges from intentional dialogue across disciplines. However, she is clear that shared goals are the foundation for extracting those ideas meaningfully. Without common purpose, even diverse teams can become fragmented. Trust-building, in her view, requires consistent delivery, expectation management, and transparency. She strives to keep her promises, communicates constraints openly, and balances optimism with realism. She views culture as the accumulation of behaviour, underscoring the importance of consistent actions and clear communication in shaping a cohesive and connected team identity. Akiko also makes intentional efforts to keep her Japan-based office plugged into the global organization by fostering English-language meetings and inter-office collaboration. She believes that inclusion means not only being open to new ideas but actively drawing them out, especially in Japan where silence is often misread by Western leaders. Her advice for foreign leaders in Japan centres on listening more than speaking, respecting the local communication style, and recognizing that lack of feedback doesn't imply satisfaction. For aspiring female leaders, her message is one of encouragement—step forward, trust those who support you, and don't be deterred by fear. Her leadership is marked by resilience, clarity, and a deep commitment to enabling others to lead and succeed in their own right. Master the Art of Persuasion In today's business world, persuasion is essential. Yet most professionals lack this critical skill, watching their ideas go nowhere. What if you could command attention and have your recommendations consistently adopted? This game-changing ability isn't just for "natural communicators"—it's a skill you can master. There is a perfect solution for you- to LEARN MORE click here (https://bit.ly/3VhvR2B) To get your free guide “How To Stop Wasting Money On Training” click here ( https://bit.ly/4agbvLj ) To get your free “Goal Setting Blueprint 2.0” click here (https://bit.ly/43o5FVK) If you enjoy our content, then head over to www.dale-carnegie.co.jp and check out our Japanese and English seminars, workshops, course information and schedules and our whitepapers, guidebooks, training videos, podcasts, blogs. About The Author Dr. Greg Story, President Dale Carnegie Tokyo Training Contact me at greg.story@dalecarnegie.com Bestselling author of “Japan Sales Mastery” (the Japanese translation is "The Eigyo" (The営業), “Japan Business Mastery” and "Japan Presentations Mastery".  He has also written "How To Stop Wasting Money On Training" and the translation "Toreningu De Okane Wo Muda Ni Suru No Wa Yamemashoo" (トレーニングでお金を無駄にするのは止めましょう) and his brand new book is “Japan Leadership Mastery”.   Dr. Greg Story is an international keynote speaker, an executive coach, and a thought leader in the four critical areas for business people: leadership, communication, sales and presentations. He leads the Dale Carnegie Franchise in Tokyo which traces its roots straight back to the very establishment of Dale Carnegie in Japan in 1963 by Mr. Frank Mochizuki. He publishes daily blogs on LinkedIn, Facebook and Twitter Has 6 weekly podcasts: 1.     Mondays -  The Leadership Japan Series, 2.    Tuesdays – The Presentations Japan Series Every second Tuesday - ビジネス達人の教え 3.    Wednesdays - The Sales Japan Series 4.    Thursdays – The Leadership Japan Series Also every second Thursday - ビジネスプロポッドキャスト 5.    Fridays - The Japan Business Mastery Show 6.    Saturdays – Japan's Top Business Interviews Has 3 weekly TV shows on YouTube: 1.     Mondays - The Cutting Edge Japan Business Show Also every Second Thursday - ビジネスプロTV 2.    Fridays – Japan Business Mastery 3.    Saturdays – Japan Top Business Interviews In the course of his career Dr. Greg Story has moved from the academic world, to consulting, investments, trade representation, international diplomacy, retail banking and people development. Growing up in Brisbane, Australia he never imagined he would have a Ph.D. in Japanese decision-making, become a 40 year veteran of Japan and run his own company in Tokyo. Since 1971, he has been a disciple of traditional Shitoryu Karate (糸東流) and is currently a 6th Dan. Bunbu Ryodo (文武両道-both pen & sword) is his mantra and he applies martial art philosophies and strategies to business.    

In this episode of Voices of Otolaryngology, join Rahul K. Shah, MD, MBA, AAO-HNS/F Executive Vice President and CEO as he interviews Dana M. Thompson, MD, MS, MBA, AAO-HNS 2024 Hall of Distinction inductee and Division Head of Otorhinolaryngology-Head and Neck Surgery and the Lauren D. Holinger Professor and Chair of Pediatric Otolaryngology at the Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, about transforming "pipelines" into "pathways" for diversity in medicine.  Discover her five guiding values and learn how her family legacy shaped her commitment to addressing healthcare disparities through mentorship, inclusion, and value-based care reforms. This episode was recorded during The Triological Society 2025 Combined Sections Meeting, January 23-25, 2025, in Orlando, Florida. 

Esther Muña, Chief Executive Officer of the Commonwealth Healthcare Corporation and Territorial Health Official for the Northern Mariana Islands, explains how their Public Health Infrastructure Grant (PHIG) funds allowed them to improve security and integrate care through a new electronic health record system; Jerry Larkin, Director of the Department of Health of Rhode Island, describes how PHIG has been an asset to his department in preventing illness and enabling advancements; Jacki Tulafono, Division Head for the Department of Health in American Samoa, shares how PHIG dollars support key functions at their agency, allowing them to provide services to those that need it most. PHIG Partners Web Page PHIG Newsletter

Fifty years after the founding of Microsoft, the CEO of its artificial intelligence division has a big task: develop a new product line that is as integral to daily life as the software giant's past innovations. “We're really trying to land this idea that everybody is going to have their own personalized AI companion," said Mustafa Suleyman in an interview with The Associated Press. "It will, over time, have its own name, its own style. It will adapt to you. It may also have its own visual appearance and expressions.” Suleyman laid out that vision on Microsoft's 50th anniversary in April. The company's flagship product of this AI era, Copilot, already combines a chatbot with Microsoft's suite of workaday tools, from Excel spreadsheets and PowerPoint presentations to the Windows operating system that defines how most computers work. But Suleyman is striving for something that sounds a little more like science fiction—a technology that can form a “lasting, meaningful relationship” with its users. “One that knows your name, gets to know you, has a memory of everything that you've shared with it and talked about and really comes to kind of live life alongside you,” he said. “It's far more than just a piece of software or a tool. It is unlike anything we've really ever created." Some of those updates—such as new “visual memory” capabilities that keep track of a user's digital activity, if they want that—rolled out on mobile apps last month. Other features are still in development, such as an animated avatar—a talking peacock in Suleyman's demo—that would embody a person's AI companion. “It's a super competitive market, but this is absolutely foundational to us,” Suleyman said. “Copilot in the workplace, Copilot at home is the future of the company. On the consumer side, we are going to be committed to this for many decades to come. We really think it's the major platform shift that we have to win.” Even as competition ramps up, so does wariness from Wall Street and big business customers about whether these AI products are worth their huge costs in computing power and energy. This article was provided by The Associated Press.

You can text us here with any comments, questions, or thoughts!In this encore episode, Kemi welcomes Dr. Tamorah Lewis, a neonatologist and pediatric clinical pharmacologist, to discuss the intricate dance of motherhood and career. Together, they explore the challenges and triumphs of being high-achieving women of color in academia.   Join Kemi and Dr. Lewis as they candidly reflect on their personal journeys, the evolving definition of success in motherhood, the vital role of supportive partnerships and the intentional steps we can take to empower our children.  Highlights from this episode: Embracing Imperfections in Motherhood The Importance of Self-Worth and Identity Navigating Career and Family Dynamics The Role of Support Systems in Parenting Redefining Success as a Working Mother  Loved this convo? Please go find Dr. Lewis on X (fka Twitter) @TamorahLewisMD and show her some love!  More about Dr. Tamorah Lewis, MD, PhD - Dr. Tamorah is a physician scientist and the Division Head for Clinical Pharmacology and Toxicology at SickKids. In this role, her goal is to advance the hospital-wide vision for Precision Child Health and collaborate with multiple clinical Divisions to research and implement precision therapeutics. She will provide clinical care in the Level IV NICU at SickKids. Prior to this new role, Lewis was at Children's Mercy Kansas City in the Divisions of Neonatology and Pediatric Clinical Pharmacology for seven years. She worked as an attending in the Level IV NICU and led translational / clinical research in neonatal pharmacology.  If you'd like to learn more foundational career navigation concepts for women of color in academic medicine and public health, sign up for our KD Coaching Foundations Series: www.kemidoll.com/foundations.  REMINDER: Your Unapologetic Career Podcast now releases episode every other week! Can't wait that long? Be sure you are signed up for our newsletter (above) where there are NEW issues every month! 

Dr. Joseph Kanter, ASTHO CEO, highlights public health workers as National Public Health Week wraps up this weekend; Dr. Scott Harris, ASTHO President and Alabama State Health Officer, outlines public health priorities to Congress; Jacki Tulafono, Division Head for the Department of Health in American Samoa, explains why ASTHO's Spring Leadership Forum was such a valuable experience. American Public Health Association Web Page: National Public Health Week ASTHO News Release: ASTHO President Scott Harris, MD, MPH, Testifies to Congress Advocating for Sustainable and Predictable Public Health Funding Labor, Health and Human Services, and Education - Public Witness Day ASTHO Public Health Review Morning Edition Episode 882: Harris Testifies on Hill, 2025 TFAH Report ASSTHO Web Page: Subscribe  

In collaboration with the Women in Otolaryngology (WIO) Section of the American Academy of Otolaryngology Head and Neck Surgery. Join me as I discuss The Double Bind with Dana Thompson, MD, the Lauren D. Holinger Professor and Division Head of Pediatric Otolaryngology at Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine.

In this episode, hosts Drs. Temara Hajjat and Peter Lu  talk to Dr. Sean Moore about the impact of global health research on pediatric gastroenterology nationally and internationally.  Dr. Moore is a pediatric gastroenterologist and Division Head at Cincinnati Children's Hospital and Medical Center and a Professor of Pediatrics at University of Cincinnati School of Medicine.  Learning Objectives:Understand the value of global health research in pediatric GI.Understand the impact of global health research on development of resources nationally and internationally. Recognize the approach to global health in pediatric GI.Support the showThis episode may be eligible for CME credit! Once you have listened to the episode, click this link to claim your credit. Credit is available to NASPGHAN members (if you are not a member, you should probably sign up). And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

With AI now more accessible than ever, its impact on learning and educational equity is rapidly evolving. This series will share hidden challenges, real-world use cases, and actionable strategies for navigating the future of AI in education.This is the last of three episodes and focuses on responsible AI use for parents.ABOUT AMBER BERRYAmber Berry is a trailblazer in the field of AI and education, serving as the inaugural Vice President of AI and Strategy for Middle States Association (MSA). In this role, Amber cofounded RAIL: Responsible AI in Learning, shaping the future of accreditation and school improvement. With over 15 years of school experience spanning both public and independent education, she has held positions of increasing responsibility, including Division Head and Director of Teaching Fellows at St. Luke's School in Connecticut.Amber's thought leadership in responsible AI adoption is grounded in her rich educational background. A graduate of Princeton University with a B.A. in French & Italian, she earned her M.A. in Linguistics and Pedagogy from Middlebury College and an M.Ed. in Private School Leadership from Columbia University. Most recently, she added a Mini-MBA in AI for Business to her impressive credentials, amplifying her expertise in leveraging AI for strategic innovation.Amber is a sought-after speaker, an advocate for equitable AI practices, and a member of Excelle Collective for women in educational leadership. At home, she balances her roles as a devoted mom, NFL wife, and active community leader, inspiring others to embrace transformation in every sphere of life.Follow us at @artic.ulating on IG for more of Articulating!

Dr. Cory Goldberg is a Plastic and Craniofacial Surgeon and former Division Head of Plastic Surgery at Trillium Health Partners, certified by both the Royal College of Physicians and Surgeons of Canada and the American Board of Plastic Surgery. Combining his medical expertise with an MBA in International Business, he not only performs a full range of cosmetic procedures at his Toronto practice but also volunteers with Operation Smile worldwide, while serving as a business development consultant for major pharmaceutical companies and healthcare initiatives. Become the best husband and leader you can: https://www.thedadedge.com/mastermind Today, Dr. Cory Goldberg opens up about his personal health transformation, losing 50 pounds and undergoing surgery himself, which not only improved his wellbeing but made him a more empathetic surgeon while highlighting the importance of self-care for men who often neglect their own health. The conversation delves into crucial health topics including oxidative stress and its impact on aging and disease, with Dr. Cory Goldberg explaining how negatively charged oxygen molecules can damage DNA and contribute to various health issues.  He offers practical advice on managing oxidative stress through diet, exercise, and maintaining social connections, a key factor in longevity, while sharing his top recommendations for a healthy life, including plant-based eating and supplements like glycidin to combat aging at the cellular level. ---------------------------- Gentlemen, if you're ready to level up, don't miss The Forge: A Gathering of Men—an exclusive event created by leaders like Connor Beaton, Larry Hagner, Matt Beaudreau, and Ryan Michler to help you connect, grow, and become the best version of yourself. Learn more at The Men's Forge. ---------------------------- www.thedadedge.com/516 www.themensforge.com | www.thedadedge.com/alliance Facebook | Instagram | X | YouTube www.corygoldbergmd.com | www.beautyspan.com | GliSODin® Skin Nutrients  

With AI now more accessible than ever, its impact on learning and educational equity is rapidly evolving. This series will share hidden challenges, real-world use cases, and actionable strategies for navigating the future of AI in education.This is the second of three episodes and focuses on responsible AI use for students.ABOUT AMBER BERRYAmber Berry is a trailblazer in the field of AI and education, serving as the inaugural Vice President of AI and Strategy for Middle States Association (MSA). In this role, Amber cofounded RAIL: Responsible AI in Learning, shaping the future of accreditation and school improvement. With over 15 years of school experience spanning both public and independent education, she has held positions of increasing responsibility, including Division Head and Director of Teaching Fellows at St. Luke's School in Connecticut.Amber's thought leadership in responsible AI adoption is grounded in her rich educational background. A graduate of Princeton University with a B.A. in French & Italian, she earned her M.A. in Linguistics and Pedagogy from Middlebury College and an M.Ed. in Private School Leadership from Columbia University. Most recently, she added a Mini-MBA in AI for Business to her impressive credentials, amplifying her expertise in leveraging AI for strategic innovation.Amber is a sought-after speaker, an advocate for equitable AI practices, and a member of Excelle Collective for women in educational leadership. At home, she balances her roles as a devoted mom, NFL wife, and active community leader, inspiring others to embrace transformation in every sphere of life.Follow us at @artic.ulating on IG for more of Articulating!

With AI now more accessible than ever, its impact on learning and educational equity is rapidly evolving. This series will share hidden challenges, real-world use cases, and actionable strategies for navigating the future of AI in education.This is the first of three episodes and focuses on responsible AI use for schools.ABOUT AMBER BERRYAmber Berry is a trailblazer in the field of AI and education, serving as the inaugural Vice President of AI and Strategy for Middle States Association (MSA). In this role, Amber cofounded RAIL: Responsible AI in Learning, shaping the future of accreditation and school improvement. With over 15 years of school experience spanning both public and independent education, she has held positions of increasing responsibility, including Division Head and Director of Teaching Fellows at St. Luke's School in Connecticut.Amber's thought leadership in responsible AI adoption is grounded in her rich educational background. A graduate of Princeton University with a B.A. in French & Italian, she earned her M.A. in Linguistics and Pedagogy from Middlebury College and an M.Ed. in Private School Leadership from Columbia University. Most recently, she added a Mini-MBA in AI for Business to her impressive credentials, amplifying her expertise in leveraging AI for strategic innovation.Amber is a sought-after speaker, an advocate for equitable AI practices, and a member of Excelle Collective for women in educational leadership. At home, she balances her roles as a devoted mom, NFL wife, and active community leader, inspiring others to embrace transformation in every sphere of life.Follow us at @artic.ulating on IG for more of Articulating!

Watch this episode on YouTube hereInterventional Neuroradiology (also sometimes referred to as "endovascular neurosurgery and "interventional neurology") is a relatively young field, yet it has achieved remarkable progress since its inception. Our guest is Dr. Pascal Mosimann, our interventional neuroradiologist and Division Head, Interventional and Diagnostic Neuroradiology at University Health Network. In this episode of Radiologists we talk about what interventional neuroradiology is, why Canada is a great place to become a specialist in this field, the challenges this specialty faces today and its bright future as well as the incredible opportunities it holds, how one can become an interventional neuroradiologist and who is best suited for this field, and, as always, so much more!The content provided in this episode is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician with any questions you may have regarding a medical condition.Produced by Inna LevchukThanks for listening! Watch Radiologists on YouTube hereFollow us on: XInstagramLinkedInVisit our website: imagingtoronto.com

In this episode of the Concrete Logic Podcast, Seth Tandett interviews Colin Lobo, the Executive Vice President and Division Head of Engineering at NRMCA. They delve into the differences between prescriptive and performance specifications in concrete, discussing the implications of each on responsibility, compliance, and industry practices. Colin explains the evolution from prescriptive to performance specifications, the challenges of hybrid specifications, and the importance of accurate documentation in concrete mixing. The conversation highlights the challenges faced in job site testing, the importance of density measurement, and the need for improved testing standards to ensure safety and sustainability. The discussion also touches on the shift towards performance-based specifications and the confidentiality issues surrounding mix designs.Takeaways • Prescriptive specifications dictate how to mix concrete. • Performance specifications focus on the desired outcomes. • Responsibility shifts to the concrete producer with performance specs. • Hybrid specifications can create contradictions in requirements. • Water quality is a significant concern in concrete mixing. • Testing specimens often get compromised, affecting strength measurements. • Current testing standards are inadequate and need improvement. • Sustainability efforts could be increasing the carbon footprint of concrete. • Industry standards must evolve to reflect practical realities. • Collaboration is needed to improve testing and standards. • Engagement in standards committees is vital for industry progress. Chapters 00:00 Introduction to Concrete Specifications 03:25 Understanding Prescriptive vs Performance Specifications 07:30 The Shift in Responsibility 09:50 Hybrid Specifications and Their Challenges 11:46 The Role of Legal in Specification Acceptance 13:24 Concrete Producer's Perspective on Specifications 15:09 Documenting Compliance in Concrete Mixing 16:40 Typical Prescriptive Requirements 19:24 Evolution from Prescriptive to Performance Specifications 21:20 Challenges in Concrete Testing 24:29 Mix Design and Performance Expectations 27:27 The Importance of Density Measurement 29:52 Addressing Testing Standards and Sustainability 32:19 Evolving Towards Performance-Based Specifications 35:18 Confidentiality and Industry Standards***Did you learn something from this episode? Would you like to support the concrete industry's favorite podcast? If so, donate at https://www.concretelogicpodcast.com/support/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ . When YOU donate to the show, you will be listed as a producer of the next episode that is released! Join the Concrete Logic Academy! Enhance your learning from our podcast with engaging quizzes that test your knowledge and help you earn Professional Development Hours (PDHs). Support Concrete Logic and take your education to the next level!

Dr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital. And he is the president of the CDA.

November 14, 2024 ~ Manu Malhotra, MD, MBA, FACEP, Interim Chief Medical Officer, Henry Ford Health, and Chief Medical Officer, Henry Ford West Bloomfield Hospital and Northwest Market and Steven Rockoff, DO, Division Head, Department of Emergency Medicine, Henry Ford West Bloomfield Hospital talk emergency care at Henry Ford West Bloomfield Hospital and across Henry Ford Health.

Anti-seizure medications are the mainstay of epilepsy treatment, but these medications are not effective for all forms of epilepsy, such as Lennox-Gastaut syndrome or LGS. It's a rare form of epilepsy that has no cure. Dr. Sandi Lam, Division Head, Neurosurgery at Lurie Children's,  is working to help pediatric patients with LGS and their families manage this condition by investigating the outcomes that matter most to patients and their families. In this episode, Dr. Lam talks about this important work and how it may help build a roadmap that will empower the future of research for LGS and other pediatric epilepsies and rare diseases.

It was a big affair.  The entire Shinsei Bank retail staff were assembled for a series of updates from the Division Heads on what each Division was doing and where they were going.  One of my erstwhile lifelong banker colleague Division Head gave his presentation.  It was dull, monotone, low energy and not engaging in the least.  Unfortunately for him, it was my turn next.  By this time, thanks to my previous work as a Senior Trade Commissioner and Consul-General for Australia,  I had given hundreds of public speeches, mainly in Japanese, to audiences of all different stripes in Japan. I knew how to give this talk in a way which would be interesting for the audience and in a way in which I could grab their attention.  My sharp elbowed colleague instantly recognised there were light years between his miserable efforts and my professionalism.  Did he commit to self-improvement, to build the biggest skyscraper in town, to become excellent in public speaking?  No.  He sought out ways to pull down all the other skyscrapers, so that his could be the tallest instead.  He informed all in earshot, except for me of course, that “Greg is all style and no substance”.  When this comment was duly reported to me, honestly, I just burst our laughing.  Not in an exaggerated thespian, ironic way, but a genuine belly laugh, because the idea was so ridiculous, so preposterous, so revealing about his insecurities.  I had given enough public speeches by that time to know it wasn't just style that was engaging my audiences.  What was ironic was that originally I was scouted to leave Austrade and join Shinsei's Retail Bank, because of a speech I gave to the American Chamber of Commerce here in Tokyo.  In fact, that speech changed the direction of my career, although I didn't realise it at the time. Recently, I was reading an article by Kathryn Brownell in the Financial Times, where she referenced the first televised debate between Kennedy and Nixon in 1960.  Nixon didn't understand the medium of television as well as Kennedy.  Kennedy saw the opportunity to speak directly to voters, rather than just relying on highlighting policy differences. I recall some reports I have come across at different times, which said that those who only listened to the debate, gave it to Nixon, while those who watched, gave it to Kennedy. Nixon certainly made the complaint that the televised debate format brought in a new era where “politicians focused on style over substance”.  It was a dividing line between eras and the future belonged to those who mastered the skills needed to be successful with the new medium. Kamala Harris killed Donald Trump in the recent debate and that wasn't just style and no substance.  She was extremely well prepared and brought all guns blazing to what Trump thought was going to be a knife fight. So what about businesspeople presenting here in Tokyo?  I recall coaching a Japanese President who forsook the opportunity to do a professional speech, because he felt his vendor audience wouldn't be ready for it.  He knew what to do but chose to not do it. That was highly perplexing to me as his coach, but standing out in Japan is never a popular course of action. He just gave the same old boring monotone performance, because that was the norm for his company and industry. It was painful for me to watch and know what he could have done instead. I saw another local businessperson give a very good performance, as he was a skilled presenter.  However, when I sat back and thought about what he was saying, as opposed to just being mesmerised by how he was saying it, I felt there wasn't much meat in that speech.  Before Covid, I saw Shigeru Ishiba, a Liberal Democratic Party hopeful, currently  trying to secure the Party Presidency and thereby become Prime Minister, give a talk as part of a panel discussion. He was slumped in his chair, looking bored and his comments were lifeless, monotone and dull.  However, when I closed my eyes and listened to what he was actually saying, it had more impact. If he wants to run this country, I hope he has improved as a communicator since then. It is obviously not a choice between style and substance.  We need both, and I want to replace the word “style” with “professionalism”, to make the point clearer.  Talking crap fluently is no help and neither is being valuable, but not being heard.  The big difference between Harris and Trump, I believe, was in their understanding of the occasion and the preparation for it.  This is precisely the same for us in business.  If we spend all of our time crafting the slide deck and none on the rehearsal, then our talk will not be optimised. Observe any public talks today and even the good speakers face some people in the crowd who have whipped out their phones and are no longer concentrating on what is being said.  Having great content, which is ignored by the audience, because we are unskilled and so boring is no better than turning up with weak content.  We fail to have any impact.  Let's wrap our numbers up in stories, so that people can remember them. Let's work on our professional delivery skills, so that we can keep the listeners with us, from start to end. Let's defeat the mobile phone, as the escape alternative to what we are saying.  By the way, it will only get worse. We have no time to lose to improve our communication capability.  

Transformative care through pediatric plastic and reconstructive surgery takes place every day at Lurie Children's Cleft Lip and Palate Repair Program. In this episode,  Dr. Arun Gosain, Division Head of Plastic Surgery at Lurie Children's, discusses the full spectrum of care the program offers to children with cleft lip and cleft palate, from birth through adulthood.

Dr. Jafar Golzarian shares his experiences with co-founding an outpatient-based lab (OBL), obtaining the right equipment, handling staffing, negotiating with insurance companies, and marketing his new practice. Dr. Golzarian is an interventional radiologist at his OBL in Minneapolis, Minnesota and he is the former Division Head and Program Director for the interventional radiology program at the University of Minnesota. --- CHECK OUT OUR SPONSOR GE Healthcare Allia Image Guided Systems https://www.gehealthcare.com/products/interventional-image-guided-systems/allia --- SYNPOSIS Dr. Golzarian emphasizes the importance of having independence and adopting a patient-centered approach. He also offers practical advice for physicians considering similar moves into the private practice sphere. Additionally, Dr. Golzarian talks about the challenges and rewards of focusing on specific embolization procedures and collaborating with industry partners to build a successful practice. --- TIMESTAMPS 00:00 - Introduction 06:06 - Setting Up a New Practice 14:27 - Tips for Marketing 23:40 - Finding the Right Business Partner 30:44 - OBL vs. ASC Status and Reimbursement 32:59 - Industry Support and Device Costs 37:58 - Staffing and Culture 45:25 - Advice for New Practitioners --- RESOURCES BackTable VI Episode #85 - Genicular Artery Embolization for OA with Dr. Jafar Golzarian: https://www.backtable.com/shows/vi/podcasts/85/genicular-artery-embolization-for-oa BackTable VI Episode #361 - Intra-Arterial & Percutaneous Treatment of Giant Hepatic Hemangiomas with Dr. Jafar Golzarian: https://www.backtable.com/shows/vi/podcasts/361/intra-arterial-percutaneous-treatment-of-giant-hepatic-hemangiomas BackTable VI Episode #447 - Exploring GAE: Clinical Insights & Outcomes with Dr. Mark Little: https://www.backtable.com/shows/vi/podcasts/447/exploring-gae-clinical-insights-outcomes GEST MSK Annual Meeting: https://www.gestmsk.com/ Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline: https://www.auanet.org/guidelines-and-quality/guidelines/benign-prostatic-hyperplasia-(bph)-guideline

Warwick City Councilor Vincent Gebhart joins the show to expand on his call for Warwick Water Division head Terry Dipetrillo to be dismissed. See omnystudio.com/listener for privacy information.

DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.       Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. Introduction to our guestToday, we dive deep into the world of cardiac surgery with our esteemed guest, Dr. Bobby Yanagawa, Division Head of Cardiac Surgery at St. Michael's Hospital. This episode unpacks the thrilling, yet demanding life of a heart surgeon, exploring everything from the adrenaline of emergency surgeries to the finesse required for elective procedures. Dr. Yanagawa, distinguished for his mastery in the realm of heart health, shares his insights on managing heart disease risk factors and the advances in surgical technology like transcatheter aortic valve replacement (TAVR). We'll also touch on the emotional weight of decision-making in life-threatening treatments, and how surgeons like Dr. Yanagawa navigate the complexities of patient care. Moreover, beyond the scalpel and sutures, we discuss the critical balance between personal life and professional dedication, aiming to unearth the reality of medical practice in contrast to its often sensationalized portrayals. So, tune in as we explore the heart of the matter on "Ditch the Labcoat."Episode Breakdown : The discussion opens with Dr. Yanagawa comparing the intensive concentration required in the operating room to entering a martial arts dojo, a place where focus is paramount and the external world fades away. This analogy extends into a broader discussion on the parallels between martial arts and medical education, emphasizing humility, continual learning, and respect for expertise.Moving through the intricacies of heart health, the conversation covers a wide array of topics, from the technological advancements in procedures like Transcatheter Aortic Valve Replacement (TAVR) to the challenges of maintaining a work-life balance in such a demanding field. Dr. Yanagawa shares insights into the surgical intricacies of managing acute emergencies like aortic dissections and the bread-and-butter of elective coronary bypass procedures.A significant portion of the dialogue focuses on the ethical and emotional dimensions of heart surgery, particularly regarding patient interactions and the decision-making process concerning surgical risks and life expectancy. The emotional weight of conveying the realities of heart surgery to patients and their families highlights the profound impact of medical professionalism and empathy in clinical practice.Moreover, Dr. Yanagawa reflects on the broader implications of modern lifestyle choices on health, contrasting today's sedentary habits with the more active, hunter-gatherer past, and how these shifts contribute to chronic health issues. This serves as a springboard into a deeper discussion on the interplay between genetics, lifestyle, and preventive health care.As the episode winds down, both doctors discuss the future of heart surgery, including the potential for growing organs in labs and the evolving role of artificial hearts. The conversation also touches on the use of different heart valves, from pig and cow valves to mechanical options, outlining the considerations that guide their use in different patient scenarios.Throughout the episode, Dr. Bonta and Dr. Yanagawa repeatedly circle back to the importance of deriving purpose from their work and the intrinsic motivation needed to navigate the pressures of the medical field. The episode not only sheds light on the technical and ethical facets of cardiac surgery but also humanizes the surgeons behind the scalpel, revealing their passions, challenges, and the delicate balance they maintain between saving lives and living their own.Topics Covered 1. Introduction to Guest and Episode Focus   - Introduction of Dr. Bobby Yanagawa, a division head of cardiac surgery at St. Michael's Hospital   - Overview of the episode's focus on heart surgery, health management, and the reality of healthcare.2. The Reality of a Surgical Career   - Dr. Yanagawa's excitement for elective and emergency procedures.   - Challenges and rewards of being a cardiothoracic surgeon and internist.3. Impact of Modern Lifestyle on Health   - Discussion on how modern living contrasts with hunter-gatherer lifestyles.   - Evolutionary lifestyle effects on human health.4. Handling Medical Emergencies and Procedures   - The thrill and pressures of dealing with medical emergencies.   - Mortality risks and emotional dimensions of discussing life-threatening treatments.5. Surgical Decision-Making and Ethics   - Patient reactions and emotional impacts when facing serious health decisions.   - Consulting with colleagues on borderline cases and ethical considerations in healthcare.6. Advancements in Medical Technology   - Discussion on the potential of growing blood vessels and organs in labs.   - Technological advancements like transcatheter aortic valve replacement (TAVR).7. Education and Mentorship in Medicine   - Importance of providing proper feedback and support to medical learners.   - Drawing parallels between martial arts training and medical education.8. Personal Motivations and Career Choices   - Dr. Yanagawa's personal reasons for becoming a heart surgeon.   - The day-to-day realities and the diversities within the medical field.9. Health Management and Chronic Diseases   - Importance of medication adherence in managing diabetes.   - The role of lifestyle modifications in managing chronic diseases.10. Work-Life Balance and Burnout    - Importance of balancing professional obligations with personal life.    - Strategies to avoid burnout and maintain a fulfilling career.11. Discussion on Heart Valves and Prostheses    - Different types of heart valves and their suitability for various patients.    - Future possibilities and current limitations of artificial heart technology.12. Concluding Thoughts    - Reflections on deriving purpose from work and making a difference.    - Recap of the importance of a real understanding of the healthcare profession beyond media portrayals.This sequence offers a structured breakdown of the episode's discussion, providing a clear roadmap for listeners to understand the complexities and nuances of a career in heart surgery as well as broader healthcare issues.

Connecticut lawmakers are debating a bill to bring earlier intervention to children diagnosed with Duchenne muscular dystrophy. House Bill 5321 would require all newborns in the state be tested for DMD as part of the Department of Public Health's newborn screening program. If approved, it would begin in July 2027. We got a medical perspective on the impact of this bill if it passes. Dr. Gyula Acsadi is a pediatric neurologist and Division Head of Neurology at Connecticut Children's Hospital. Image Credit: Getty Images

In acquisition, we often have to strike a balance between getting gear out quickly and abiding by federal contract regulations. However, in some cases our command is able to use specific contract vehicles to better meet the “speed of need.” On this episode, Morgan chats with Jack Cave, Division Head for Program Support. The views expressed in this podcast reflect those of the speakers and do not necessarily reflect the views, policies, or positions or the United States Marine Corps or Department of Defense. Show notes: Favorite TV show: Doc Talk --- Send in a voice message: https://podcasters.spotify.com/pod/show/equipping-the-corps/message

Missouri Children's Division Director Darrell Missey talks about where the massive backlog of child abuse and neglect case investigations stands, and other issues affecting children in the state. Last year, St. Louis Public Radio reported that the division's office serving St. Louis and St. Louis County had a backlog of 6,124 cases that remained open after 45 days. Missey describes the division's improvements since then, and where things stand now.

The leader of Missouri's agency responsible for investigating child abuse and neglect says its St. Louis office is making progress in eliminating a massive case backlog. Last year, St. Louis Public Radio reported on the troubles in the Children's Division office in St. Louis, which serves the city and St. Louis County. A combination of high turnover and inability to hire people created a backlog of 6,124 cases of abuse or neglect allegations that remained open after 45 days. And the staff's 16 investigators had an average caseload of 150 — when federal guidelines say it should be closer to 10 to 12. In a wide-ranging interview on Wednesday, Children's Division Director Darrell Missey said that increased hiring should play a major role in eliminating overdue cases over the next few months. Missey said the agency is close to reaching its goal of having 60 investigators to look into abuse and neglect claims in St. Louis and St. Louis County.

This week on The Hamilton Review Podcast, we are honored to welcome Dr. Arjumand Siddiqi to the show. In this in depth conversation Dr. Siddiqi and Dr. Bob discuss an article in the Wall Street Journal that Dr. Siddiqi contributed to entitled: "Jump in Infant Mortality Rate Reverses Long Decline."  Why is the infant mortality rate going up in the United States? Don't miss this critical discussion. Arjumand Siddiqi is Professor, Division Head of Epidemiology, and Canada Research Chair in Population Health Equity at the Dalla Lana School of Public Health, University of Toronto. She also holds appointments in Sociology, Public Policy, and Women and Gender Studies at University of Toronto, and adjunct professorships at Harvard University and the University of North Carolina – Chapel Hill. Dr. Siddiqi's research focuses on understanding the nature and causes of health inequities, with particular emphasis on how they are influenced by social policies and other societal conditions. Dr. Siddiqi frequently speaks to and works with stakeholder institutions, including federal, provincial, and local governments, and international agencies. She was a member of the World Health Organization Commission on Social Determinants of Health. She is the recipient of the 2022 Canadian Institutes of Health Research, Institute of Population and Public Health Mid-Career Trailblazer Award.  She received her doctorate in Social Epidemiology from the Harvard T.H. Chan School of Public Health. How to contact Dr. Arjumand Siddiqi: Dr. Arjumand Siddiqi Webpage How to contact Dr. Bob: Dr. Bob on YouTube: https://www.youtube.com/channel/UChztMVtPCLJkiXvv7H5tpDQ Dr. Bob on Instagram: https://www.instagram.com/drroberthamilton/ Dr. Bob on Facebook: https://www.facebook.com/bob.hamilton.1656 Dr. Bob's Seven Secrets Of The Newborn website: https://7secretsofthenewborn.com/ Dr. Bob's website: https://roberthamiltonmd.com/ Pacific Ocean Pediatrics: http://www.pacificoceanpediatrics.com/

Leaders may not even be aware that they are poor listeners.  They are very focused on telling others what to do. Being time poor, they are very focused on their own messaging, rather than the messaging efforts of others.  In the war for talent in Japan, that could be a fatal move.  One of the biggest factors driving engagement in Japan is the feeling that the boss values you.  If the leader isn't really listening to the team members, they are not stupid and they will pick up on this.  Before you know it, they have fled to greener pastures.  They are off to your competitor, and the arduous and expensive task of replacing them begins.  We don't want that. Here are some hints on making sure you are a gold medal winning listening boss. 1.        You display an open and accepting attitude toward the speaker This sounds easy, but are we doing it?  Have we stopped the noise in our own brain to refocus on the person in front of us and not let that internal message competition diminish our capacity to listen to what we are being told?  Are we in a neutral mindset and not bringing up silent annoyances from past associations with this person?  Maybe they screwed something up recently and your mind is having flashbacks while they are talking to you and you are thinking about what happened.  How is your body language control?  I remember I caught myself shaking my head in disagreement while someone was telling me their idea.  It was something I didn't agree with and I was showing it.  It was an automatic physical reaction. I realised right there that I couldn't allow that to happen again. Now, I try to keep a strong lock on my body language, in case I am communicating a negative message. 2.        When someone approaches me with a question, I stop what I am doing and give them my full attention I worked with a fellow Division Head once who was a shocker. When I visited his workstation, he had three screens set up and while I was sitting there talking; he continued to multi-task.  He would type away, reading the screen and listening to me, all at the same time.  It was a total insult in my mind.  His self-awareness was dismally low and I remember how it made me feel.  So, I made a pact with myself to never do this to others. Whenever my staff comes to me while I am typing, I physically lift the keyboard up and rest it against my computer stand to show I am not doing anything else but listening to them.  I find this a good discipline, because when I am concentrating, the temptation is to type and listen at the same time – bad idea! 3.        I concentrate on what is being said even if it is of little interest to me I saw a dramatic demonstration of this by my old boss.  He was a senior Director in the firm and had a very big job.  One evening, I was sitting in his office as he was explaining something to me, when one of the secretaries popped her head in the door to say something to him as she was leaving.  It was a light comment from her, nothing particularly important, but he stopped talking to me immediately and gave her his 100% concentration.  I thought “Wow, that is impressive”. He made her feel like a million dollars. No wonder he was one of the most popular leaders in that hierarchical, tough, hard edged, cutthroat world of serious big ticket real estate. It is hard to focus on things we don't consider important, because so much of our day is taken up with Quadrant One urgent and important items.  The interruption seems like a waste of our valuable time.  It might be important to them, but not to us. We have a lot to do baby, so the temptation is to brush them off and get back to the grindstone.  We have to overcome that habit and really appreciate that this topic is important to them. If they are important to the firm, then we have to give them our full attention to show we value them. 4.        I try to understand the viewpoint of the person who I disagree with This is not easy.  Leaders are often very forceful people, used to breaking down walls and pushing forward regardless of the obstacles.  When we get pushback, we overcome it and drive hard toward the outcomes we want.  That becomes an automatic reaction and when combined with impatience, it can be a lethal cocktail. The person we are talking to has come to a conclusion based on a series of factors – their experience, what they have read, what they have heard, etc.  They feel their viewpoint is valuable and legitimate. Here we are sloughing them off and not taking them seriously.  This will drive people out the door at breakneck speed to the welcoming arms of our rivals.  It is probably killing us, but we have to suspend judgement and accept that there may be many paths to the mountaintop and they may have discovered an alternate route.  Maybe we are unmoved by their idea, but at least we have to afford them the respect of taking them seriously and listening carefully to what they have to say.  As leaders, we think we are good listeners, but often we are good tellers and poor listeners in reality.  How did you fare with this short checklist about your listening skills?  We can all do better. These little hints are excellent reminders of best practice to retain staff.  We need to build the culture internally where people feel valued and want to stay with the firm.  The alternative is expensive, disruptive and very time consuming, if people leave us during this Japan war for talent.  Listening to our people is a vital skill we need to improve to protect and grow the business.      

You ask, they answer. From the National Eczema Association, this is Eczema Answered, where wold-class experts answer your question about eczema. Here's what you asked: "Why is there no cure for eczema?" Donald Y M Leung, MD, PhD, is a Distinguished Professor of Pediatrics, allergist and immunologist at National Jewish Health. Dr. Leung serves as Division Head of Pediatric Allergy and Clinical Immunology. Do you have a question about eczema that you want answered? Email us at podcast@nationaleczema.org ⁠⁠National Eczema Association⁠⁠ The National Eczema Association is the driving force for an eczema community fueled by knowledge, strengthened through collective action and propelled by the promise for a better future.

Jason Bock, Co-Founder and CEO of CTMC, and Dr. Chris Flowers, Division Head of Cancer Medicine and Chair of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, are collaborating to accelerate the development of cancer cell therapies and manufacturing innovative cell therapies for cancer patients. CTMC is a joint venture between MD Anderson Cancer Center and National Resilience created to address the challenges of delivering autologous cell therapies at a scalable level. Jason and Chris highlight the value of face-to-face interaction in solving the complex logistics of getting a drug from the research into the clinic.   Jason explains, "We created CTMC to address the challenges of delivering autologous cell therapies to treat cancer patients. This modality is unique in that the starting material for each batch of product comes from the patient. And so, the actual manufacturing supply chain starts with the patient. We bring that into the manufacturing facility, engineer the cells, expand them, and then reinfuse those to the same patient. The clinic and manufacturing site relationship is much more connected than any other therapeutic modality. MD Anderson, being a leader in cancer cell therapy and seeing that cell therapy would be transformative for cancer treatment, we created this venture to address better the challenge of the connectedness between cell therapy, clinical trials, and manufacturing sites." Chris elaborates, "Our group at MD Anderson had a very similar concept and idea that started a little bit later, about five years after that and looking at the same target. Throughout the last three years, our group has collaborated with CTMC and has taken the concept of that target and moved it from animal models and cell models where we were testing to see whether this was a good target and effective of killing lymphoma cells. We took this to animal models, where we tested and showed that it was effective. Then, collaborating with CTMC to go through the entire FDA regulatory process to get an IND approval to develop the manufacturing process. So, not just a targeted cell therapy that was effective in the lab, but a targeted cell therapy that could be effective and be administered to patients. That whole scale-up and manufacturing process was a collaboration that happen with CTMC." #CTMC #MDAnderson #CellTherapy #ClinicalTrials #EndCancer #BiopharmaceuticalManufacturing ctmc.com    mdanderson.org Listen to the podcast here 

Jason Bock, Co-Founder and CEO of CTMC, and Dr. Chris Flowers, Division Head of Cancer Medicine and Chair of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, are collaborating to accelerate the development of cancer cell therapies and manufacturing innovative cell therapies for cancer patients. CTMC is a joint venture between MD Anderson Cancer Center and National Resilience created to address the challenges of delivering autologous cell therapies at a scalable level. Jason and Chris highlight the value of face-to-face interaction in solving the complex logistics of getting a drug from the research into the clinic.   Jason explains, "We created CTMC to address the challenges of delivering autologous cell therapies to treat cancer patients. This modality is unique in that the starting material for each batch of product comes from the patient. And so, the actual manufacturing supply chain starts with the patient. We bring that into the manufacturing facility, engineer the cells, expand them, and then reinfuse those to the same patient. The clinic and manufacturing site relationship is much more connected than any other therapeutic modality. MD Anderson, being a leader in cancer cell therapy and seeing that cell therapy would be transformative for cancer treatment, we created this venture to address better the challenge of the connectedness between cell therapy, clinical trials, and manufacturing sites." Chris elaborates, "Our group at MD Anderson had a very similar concept and idea that started a little bit later, about five years after that and looking at the same target. Throughout the last three years, our group has collaborated with CTMC and has taken the concept of that target and moved it from animal models and cell models where we were testing to see whether this was a good target and effective of killing lymphoma cells. We took this to animal models, where we tested and showed that it was effective. Then, collaborating with CTMC to go through the entire FDA regulatory process to get an IND approval to develop the manufacturing process. So, not just a targeted cell therapy that was effective in the lab, but a targeted cell therapy that could be effective and be administered to patients. That whole scale-up and manufacturing process was a collaboration that happen with CTMC." #CTMC #MDAnderson #CellTherapy #ClinicalTrials #EndCancer #BiopharmaceuticalManufacturing ctmc.com    mdanderson.org Download the transcript here 

Dr. Matt Chia and Dr. Ezra Schwartz (@ezraschwartz10) continue the exploration of how vascular surgeons and patients communicate. They discuss how we share stories with one another and what may get lost in translation.   We are excited to welcome Katie Wright (@Translucentone) and Dr. Sherene Shalhub (@ShereneShalhub) to discuss the patient experience of living with Vascular Ehlers-Danlos Syndrome or vEDS.   Katie Wright is the vEDS Natural History Study project coordinator in the Division of Vascular Surgery at Oregon Health & Science University, a podcaster, and a patient advocate. They served as the Director of the Marfan Foundation's vEDS Division, The VEDS Movement until this past March, and they sit on the VEDS Collaborative (@vEDSCollabo) and Aortic Dissection Collaborative (@ADCollab) advisory board. Katie was diagnosed with vEDS in 2017 at the age of 28. Shortly after diagnosis, they started raising awareness and fostering community through YouTube videos. Katie then began a podcast titled Staying Connected, a space to share the stories of other patients and patient families. In 2018, Katie started volunteering on the advisory board of the vEDS Collaborative, a patient-centered research collaborative group led by Dr. Sherene Shalhub.    Dr. Sherene Shalhub is the inaugural John M. Porter Chair in Vascular Surgery and Division Head of the Division of Vascular and Endovascular Surgery at Oregon Health & Science University. She is also the Vice Chair of Regional Strategy & Surgical Operations for the Department of Surgery. Dr. Shalhub's research interests focus on improving healthcare and outcomes for those with genetic vascular conditions. She is the lead investigator for the vEDS Collaborative Natural History Study and the PCORI-funded Aortic Dissection Collaborative. Dr. Shalhub obtained an MPH followed by her medical degree at the University of South Florida. Dr. Shalhub completed her general surgery training at the University of Washington. She then pursued fellowships in trauma research and vascular surgery at the University of Washington.   Resources:   The VEDS Movement  VEDS Collaborative & Natural History Study If you are interested in taking part in the study or would like more information, please contact the study team VEDSColl@ohsu.edu Donate to the vEDS Natural History Study here. Aortic Dissection Collaborative for Patient-Centered Research | BeCertain.org Staying connected Episode: What Medical Professionals Should Know about VEDS Splenic artery pathology presentation, operative interventions, and outcomes in 88 patients with vascular Ehlers-Danlos syndrome Open repair of abdominal aortic aneurysms in patients with vascular Ehlers-Danlos syndrome Audible Bleeding Exam Prep Aortopathies Episode with Dr. Shalhub Free Chime Sound Effects Download - Pixabay   Follow us @audiblebleeding Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.

Sun, stress, and gravity take a toll on our appearance as we age. But there are ways to reverse the visible signs of aging and get rid of wrinkles and sagging skin. A mini facelift could help turn back the hands of time and restore a more youthful appearance. In this episode of San Diego Health, host Susan Taylor and Salvatore Pacella, MD, Division Head of plastic and reconstructive surgery at Scripps Clinic & Scripps Green Hospital, discuss how a mini facelift is performed, how it differs from a traditional facelift, and who's a candidate. Dr. Pacella also covers the risks and recovery time.

In this episode of Critical Matters, Dr. Zanotti is joined by Dr. Nitin Puri. As a critical care physician, Dr. Puri is the Division Head for Critical Care Medicine, and Co-Director for the Center for Critical Care Medicine at Cooper University Health System. He is an Associate Professor of Medicine at Cooper Medical School of Rowan University, in Camden, New Jersey. Together, they discuss medical errors in healthcare. Additional Resources: “To Err is Human: Building a Safer Health System.” The landmark publication y the Institute of Medicine highlighting medical errors as a critical cause of deaths in the US healthcare system: https://www.ncbi.nlm.nih.gov/pubmed/25077248 Medical error – the third leading cause of death in the US: https://www.ncbi.nlm.nih.gov/pubmed/27143499 The Safety of Inpatient Health Care. New England Journal of Medicine 2023; https://www.nejm.org/doi/full/10.1056/NEJMsa2206117 The Communication and Optimal Resolution (CANDOR) toolkit from the Agency for Healthcare Research and Quality (AHRQ). CANDOR is a process that health care institutions and providers can use to respond in a timely, thorough and fair way when medical errors occur and cause patient's harm: https://www.ahrq.gov/professionals/quality-patient-safety/patient-safety-resources/resources/candor/introduction.html A powerful video on to topic of disclosure of medical errors. Worth a view: https://www.youtube.com/watch?time_continue=4&v=xeMWizTodYw Books Mentioned in this Episode: The Fearless Organization: Creating Psychological Safety in the Workplace for Learning, Innovation, and Growth. By Amy Edmondson: https://bit.ly/3OQe1zV Pachinko. By Min Lee Jee: https://bit.ly/3DNJegK

This episode is all about the intersection of motherhood and ambition, particularly for high-achieving Black women!We are so excited to welcome Dr. Tamorah Lewis to the podcast! Dr. Lewis is a physician-scientist (MD PhD), Division Head for Clinical Pharmacology and Toxicology at SickKids in Toronto, Canada and is a proud mother of three children, Quinton (13), Lydia (10), and Elijah (6).  Listen in as Kemi and Tamorah discuss the intricacies of balancing ambition and motherhood. They emphasize the importance of nurturing emotional intelligence, self-worth, and character in their children while recognizing the value of building a supportive village to help them thrive. Highlights from this episode:Redefining success as a working motherChallenges and triumphs of motherhoodThe power of representing Black cultureThe evolving parent-child relationshipRejecting the "Either/Or" narrative and embracing multidimensional roles as working mothersIf you enjoyed this conversation with Tamorah as much as we do, head over to Twitter @TamorahLewisMD and show her some love!And if you'd like to learn more foundational career navigation concepts for women of color in academic medicine and public health, sign up for our KD Coaching Foundations Series: www.kemidoll.com/foundations.

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting, and explain what it means for people with cancer. In today's episode, our guests will discuss new research in breast cancer, lymphoma, multiple myeloma, and brain tumors. First, Dr. Norah Lynn Henry discusses new research in early stage and metastatic breast cancer. Dr. Henry is Professor and Interim Chief of the University of Michigan's Division of Hematology/Oncology in the Department of Internal Medicine and the Breast Oncology Disease Lead at the Rogel Cancer Center. She is also the 2023 Cancer.Net Associate Editor for Breast Cancer. You can view Dr. Henry's disclosures at Cancer.Net. Dr. Henry: Hi, I'm Dr. Lynn Henry, a breast cancer oncologist from the University of Michigan Rogel Cancer Center. Welcome to this quick summary of the most exciting new research in breast cancer that was presented at the 2023 ASCO Annual Meeting. I have no conflicts of interest for any of the trials that I will talk about. First, I'm going to give a very brief overview of the types of breast cancer, then talk about some research that was presented on both early-stage and metastatic breast cancer. As a reminder, there are multiple kinds of breast cancer. Some breast cancers are called hormone receptor-positive or estrogen receptor-positive and are stimulated to grow by the hormone estrogen. We treat those cancers with anti-estrogen or anti-endocrine treatments, which block estrogen or lower estrogen levels. Other breast cancers are called HER2-positive. These are often more aggressive cancers. But because they have extra copies of HER2, they often respond to treatments that block HER2. Finally, there are breast cancers that don't have hormone receptors or HER2. These are called triple-negative breast cancer and are also often aggressive cancers. Most of the results I'm going to highlight today are treatments for estrogen receptor-positive and HER2-negative breast cancer. One of the main stories from the ASCO Annual Meeting was the result of the NATALEE trial. At the present time, for patients with estrogen receptor-positive, HER2-negative early-stage breast cancer who were at high risk of having their breast cancer come back, the currently recommended treatment is anti-endocrine therapy. Based on the results of a prior trial called monarchE, we also consider adding a medicine called abemaciclib, which turns off some enzymes in the cell that are called CDK4 and CDK6, which are known to make estrogen receptor-positive breast cancer cells grow. Abemaciclib can further reduce the risk of cancer recurrence compared to endocrine therapy alone, but it does have some side effects, most commonly, diarrhea. In the NATALEE trial, which was presented for the first time at this ASCO meeting, researchers studied a similar type of medication called ribociclib. It acts similarly to abemaciclib, although it is more likely to cause low blood counts and less likely to cause diarrhea. Ribociclib is currently routinely used in combination with anti-endocrine therapy to treat patients with metastatic estrogen receptor-positive breast cancer but is not yet routinely used in the early-stage setting. In the NATALEE trial, patients with estrogen receptor-positive, HER2-negative early-stage breast cancer who are at high risk of breast cancer recurrence were enrolled. Half the patients were treated with just standard anti-endocrine therapy and half also received ribociclib for 3 years. After the 3-year treatment period, those who received both ribociclib and anti-endocrine therapy were about 25% less likely to have their cancer come back compared to those who received only anti-endocrine therapy. Overall, the medication was quite well tolerated. It is important to note that this drug is not yet FDA-approved in the setting. The remaining trials I will highlight are for treatment of metastatic breast cancer. There were many trials examining how best to use drugs that we are actually already using in the clinic. For example, many presentations were about the CDK4/6 inhibitors that I just mentioned. Typically, patients who have just been diagnosed with estrogen receptor-positive, HER2-negative metastatic breast cancer get treated with anti-endocrine therapy plus a CDK4/6 inhibitor. One trial called SONIA examined whether this is the right approach, or whether patients should just get the anti-endocrine therapy up front and hold off on starting the CDK4/6 inhibitor medication until a later time. It appears that this delayed approach would reduce symptoms as well as cost of the medication, while not reducing benefit from the treatment. Therefore, it appears it is likely fine for some patients to get just anti-endocrine therapy alone initially. However, we don't know how to identify those patients. Researchers are still figuring out which patients should follow this new treatment plan and which should keep getting the double therapy at the beginning. Some more to come in the future. There was a different trial called PADA-1 that included patients taking anti-endocrine therapy and the CDK4/6 inhibitor, palbociclib, upfront. Those patients were monitored using a blood test, looking for a mutation or a change in the estrogen receptor in the cancer. Patients who had that mutation either remained on the same treatment that they'd been on or switched to the next line of therapy, even though their scans didn't show any progression of their cancer. Overall, this switching strategy looks like a very promising approach for managing patients since it may help patients' cancer respond to treatment for a longer period of time. Although this approach is not yet officially recommended according to our guidelines. In another example, many patients with all types of metastatic breast cancer are treated with a drug called capecitabine, also known as Xeloda. Although this drug is effective for many cancers, many patients experience hand-foot syndrome, nausea, diarrhea, and mouth sores. In the X7-7 clinical trial, the researchers compared the official standard FDA-approved dose based on a patient's height and weight and given for 14 days followed by 7 days off. That was compared to a fixed dose of treatment given 7 days on and 7 days off. The trial found that the fixed-dose regimen was easier to tolerate, but importantly, the benefit from the 2 doses and schedules of treatment appears to be similar. Therefore, we will likely be using this lower dose, 7 days on and 7 days off, for most of our patients who receive treatment with capecitabine for metastatic breast cancer, since it is likely to improve their quality of life while not negatively impacting the potential benefit they receive from the therapy. There were a lot of other research findings presented that are related to treatment for both early-stage and metastatic breast cancer at the meeting. Importantly, we got glimpses of the many new drugs on the horizon for treatment of breast cancer, including a new antibody-drug conjugate against HER2, as well as other new anti-endocrine and targeted treatments. We eagerly await the results of large, randomized trials so the drugs that work can be used to treat patients with breast cancer. But for now, that's it for this quick summary of important research from the 2023 ASCO Annual Meeting. Stay tuned to Cancer.Net for future updates from upcoming breast cancer conferences. Thank you. ASCO: Thank you, Dr. Henry. Next, Dr. Christopher Flowers discusses new research in lymphomas and multiple myeloma. Dr. Flowers is the Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center and Division Head ad interim of Cancer Medicine. He is also the 2023 Cancer.Net Associate Editor for Lymphoma. You can view Dr. Flowers' disclosures at Cancer.Net. Dr. Flowers: Hello. I'm Dr. Christopher Flowers, professor and chair of the Department of Lymphoma and Myeloma and interim division head for cancer medicine at the University of Texas MD Anderson. And it's my pleasure to talk to you today in this Cancer.Net podcast about latest updates in the hematological malignancies focused on lymphoid cancers from the American Society of Clinical Oncology Annual Meeting. The ASCO Annual Meeting every year is an exciting time for latest updates in the care of patients with cancer. And in particular this year, there were 3 abstracts that I'd like to highlight that were presentations at this meeting about lymphoid malignancies that have potential significant impact for patients over time. The first 2 come from a special session that was on late-breaking abstracts that were latest advances from clinical trials. The first is from the ZUMA-7 trial. This is a trial looking at axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, or CAR T-cell therapy. The CAR T-cell trial in question here was led by Jason Westin, who's a colleague of mine at MD Anderson. And MD Anderson is a partner with Kite pharmaceutical company that is a manufacturer of this and has a research alliance with that group. In the ZUMA-7 trial, this was a trial that involved the use of CAR T-cell therapy in comparison to standard-of-care therapy, which typically would be aggressive chemoimmunotherapy followed by autologous stem cell transplantation for patients with relapse of large B-cell lymphoma. As many of you may know, large B-cell lymphoma is a kind of lymphoma that is potentially curable with standard frontline therapy. And when patients relapse, the standard of care historically had been for patients to receive autologous stem cell transplantation, which is also potentially a curative therapy. This trial to do a ZUMA-7 trial compared patients who received the typical standard of care, the autologous stem cell transplant following the aggressive chemoimmunotherapy regimen for patients who had relapsed early after their initial therapy, so within 12 months, or were refractory, meaning that they did not respond to their initial therapy. And this was compared to the axicabtagene ciloleucel or axi-cel CAR T-cell therapy. The initial publication of the trial came out in the New England Journal of Medicine in 2022 and showed that the event-free survival for patients who receive CAR T-cell therapy was superior. This update of the ZUMA-7 trial at the ASCO Annual Meeting that was presented by my colleague, Jason Westin, discussed the overall survival of the study, and in this update, it showed that overall survival was also improved for patients who received axi-cel as opposed to standard-of-care therapy. And now with a median follow-up of a little bit more than 47 months, axi-cel demonstrated superiority that was statistically significant and clinically meaningful over the traditional standard of care. In that same session, there was another trial looking at CAR T-cell therapy for patients with multiple myeloma. This was a BCMA-targeted CAR T-cell therapy that was presented by Dr. Dhakal in that session providing results from the CARTITUDE-4 global randomized phase 3 clinical trial. That was a trial that involved 419 patients where patients were randomized to cilta-cel CAR T-cell therapy for myeloma or standard-of-care therapy, which in this case included combination therapy. And in this trial, this showed that single agent with a single cell-to-cell infusion significantly improved progression-free survival versus standard of care for patients with multiple myeloma who had 1 to 3 prior lines of therapy and were refractory to lenalidomide. This is also a meaningful advance for patients with this disease. And the final abstract that I'll mention is an abstract that was presented by Dr. Alex Herrera from City of Hope and was presented in the Plenary session. And it was really exciting to see a Plenary session presentation focusing on lymphomas. So this trial presented by Dr. Herrera was led by the Southwest Oncology Group. Dr. Sara Ahmed from MD Anderson, from my institution, was a participant and actively engaged in this clinical trial. This trial was a success in a number of ways. First, it involved both pediatric and adult patients and is one of the first trials of its kind to involve both large populations of patients with pediatric lymphomas as well as adults with lymphomas. It helps to consolidate the approaches that we use for Hodgkin lymphoma, both in the pediatric population and the adult population. It also represents a major advance in the ways that we conduct clinical trials in the United States in that this clinical trial finished ahead of schedule in terms of completion of the trial with collaboration from the adult and pediatric groups across the National Clinical Trials Network. As I mentioned, this was presented by Dr. Alex Herrera in the Plenary session and involved patients with stage 3, 4 Hodgkin lymphoma, where patients were randomized 1 to 1 either to receive an anti-PD-1 therapy, nivolumab, with chemotherapy, the AVD chemotherapy regimen, or the antibody-drug conjugate, brentuximab vendotin, combined with that same AVD chemotherapy. And what this showed in 994 patients who were enrolled from 2019 to 2022 was that there was a benefit for patients who received the combination of nivolumab AVD or NAVD versus the group that received brentuximab and AVD. It improved the progression-free survival in patients with advanced-stage Hodgkin lymphoma. In this trial, few immune-related adverse events were observed and a lesser number of patients went on to receive radiation therapy, which is also a benefit for patients with Hodgkin lymphoma. And this concludes my presentation of abstracts at the ASCO Annual Meeting and really exciting advances for patients with lymphoma that were presented this year. ASCO: Thank you, Dr. Flowers. Finally, Dr. Roy Strowd discusses new research in treating brain tumors, including those in people with von Hippel Lindau syndrome. Dr. Strowd is a neurologist and neuro-oncologist at Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He is also the 2023 Cancer.Net Associate Editor for Central Nervous System Tumors. You can view Dr. Strowd's disclosures at Cancer.Net. Dr. Strowd: Hello, everyone. This is Roy Strowd. I'm a physician neuro-oncologist at Wake Forest University School of Medicine in our comprehensive cancer center. And I'm really excited to be with you for this podcast on important CNS or brain tumor updates from the 2023 ASCO Annual Meeting. I don't have any relevant disclosures for the research that we'll discuss today. It was a really exciting meeting. It was actually a really fun meeting to be a brain tumor doctor at ASCO this year. So I'm really excited to talk with you about some important updates. And I think it's actually a really important time to be a patient and a caregiver and know some of the things going on in brain tumor care. So I'm going to dive into 3 studies. And one that we just have to talk about, and this was a really exciting study called the INDIGO study. At ASCO, if you present a study, you want to have a Plenary presentation, you want to be up on the big stage presenting your work. And brain tumor studies aren't always on the big stage. We just haven't had enough really good treatments out there for brain tumor patients over the years. And this year, we had a Plenary presentation, a really big study, making a big splash. And that was this INDIGO study. So I'm going to spend a few minutes talking about that study. I want brain tumor patients and caregivers to know about this and know about some of the important updates from the Annual Meeting. The study was called the INDIGO study, and it's a phase 3 study. So when you think about clinical trials, there's a phase 1, phase 2, phase 3. That phase 3 is that last step, that last hurdle that a drug needs to overcome to move towards approval. And a positive phase 3 study is really exciting for the field and means that we may have a new treatment that will change how we take care of brain tumor patients. And that's what this study was. It was also a really unique study. So it's looking at a different group of brain tumor patients, patients that have an IDH mutant glioma. Most common brain tumors that we see are the glioblastomas. And those are often and really, by rule, IDH wild-type. IDH is a gene. It's called the isocitrate dehydrogenase gene. And it's one of these really important genes for us to understand how brain tumors are going to work and how they act and it turns out, with this study, how they may respond to treatment. So this study looked at enrolling patients that had an IDH-mutant low-grade glioma, or a grade 2 glioma. Those are those often slower-growing, but they continuously grow tumors that occur early in life, typically in the 30s or 40s for young people. And we haven't really had a lot of good treatments for these patients. And so this study looked at giving a new drug that's called vorasidenib. It's hard to say vorasidenib. And it's an IDH mutant inhibitor. So it attacks that IDH mutant gene that makes these tumors what they are. And it's been undergoing development for many years. It's an exciting treatment because it's what we call a molecularly targeted treatment. It specifically targets that IDH gene that makes the low-grade tumors low-grade tumors. This study enrolled 331 patients, so a large group of patients. Half of those patients received the drug, the vorasidenib, and half received placebo. And that's pretty uncommon in cancer. We don't often do studies that are placebo-controlled studies. But for these patients, there's often not a good treatment early in the course, they get surgery. And for patients that don't need an additional treatment, we do surgery and then we wait and watch and see what happens. And that gives us an opportunity as a brain tumor community to figure out whether this type of treatment will help prevent the need for a next treatment, prevent the need for radiation and chemotherapy. And so that's what was looked at in this study. And there was some really exciting data. So I'm going to go through a few numbers, but we just got to talk about these numbers because they're really important. So at 14 months, 28% of the patients receiving the drug vorasidenib had progressions. That's about a quarter of patients compared to half that received placebo. So that's a big improvement in the number of patients whose tumor grew. So this drug prevented tumor growth in these patients. And that's exactly what we want. That's why we develop drugs, is to prevent tumor growth. When we look at the time that those patients had until they needed a next treatment or until their tumor grew, it was over 2 years of time patients receiving the drug when their tumor grew versus less than a year, 11 months for those receiving placebo. So it's adding a lot of time for brain tumor patients without tumor growth or without needing another treatment. And typically, these patients with low-grade gliomas would need something like radiation therapy or chemotherapy. And those are good treatments, and we need those treatments. But they can have toxicity. And so this is the type of drug that could prevent that toxicity, cognitive decline, other problems that can happen with chemotherapy that those patients didn't potentially suffer. So there are some important things that we learned from the INDIGO study that I would want you to take away, kind of what do these data mean? The first is that we can target this IDH gene. And that's really important for our field. And it means if you're a brain tumor patient, knowing whether your tumor is IDH mutant or IDH wild-type is important, and that's something I want brain tumor patients to ask me as a neuro-oncologist and ask their cancer doctor because that's important in deciding treatment for them. The second is this medicine vorasidenib, it gets into the brain. And that's one of the big challenges that we have in brain tumor care in developing drugs is we need things that get into the brain. And this study really shows that this is a good medicine. There's a number of IDH inhibitors, but this medicine vorasidenib is one that we want to specifically think about for our patients. And this is a practice-changing study. So for the first time, we now have a treatment that works for grade 2 gliomas and really prevents the need for radiation therapy and chemotherapy. So those are 3 important things to take away from this. There's a number of things that we don't yet know. This medicine is not available. So patients coming in and emailing me and calling me, we don't have it yet. And after a big phase 3 study like this, this is announced. There's still a number of steps that need to happen to make sure that this can be delivered to patients safely and we can get it out there. And that's in partnership with groups like the FDA, the Food and Drug Administration, and others. So this is an important conversation to have with patients, neuro-oncologists, and to know that this is something that's on the horizon. Two other things is we don't know if this is going to work for all brain tumors. In particular, for these IDH wild-type glioblastomas, the most common brain tumor, this probably is not a good therapy that we don't have any data to suggest that it would work. They don't have that IDH mutation. And so this is important for some brain tumor patients but not for everybody. And that needs to prompt a conversation with the cancer doctor. And it may not work at all times. So there's some data to suggest that this is really a drug that's best given early in the course of treatment and not later on. And so it is something that I want my patients to be aware of at the first time that I see them so we can be deciding what kind of the right time is. So I want to give folks 2 take-homes from this study and summarize a few of these things that we heard about because it's such an important study. So what are the 2 take-homes from the INDIGO Study? The first that I wrote down is targeting IDH mutation in glioma works. And that's a groundbreaking discovery from this. This is really important for our field. IDH mutations have been important to diagnose brain tumors but have never been really a therapeutic target. And this changes the landscape, and we can now target IDH mutations in gliomas. And that's really important. The second thing, the second real take-home message, is we can safely delay radiation therapy and chemotherapy in some patients with these lower-grade gliomas, potentially with IDH mutation and IDH inhibition. And that's really important. Chemotherapy and radiation therapy are important, but if we can delay those treatments and prevent side effects, that could be helpful for some of our patients. So really important update from ASCO and what I want to spend most of the time on our podcast focusing on this INDIGO study. But there were a bunch of other things going on in brain tumors at ASCO, as there always are. And I want to highlight 2 studies about some things that the groups of patients may be interested in knowing that happened at the meeting. The first is a study called the INB-200 study. And this is a phase 1 study, so it's earlier in development. But it's an immunotherapy study. And brain tumor patients and caregivers will know that we've really wanted to find an immunotherapy that works for brain tumors. And we haven't yet. And we're still not there, but this study is an important step in that direction. So this study from a group at the University of Alabama looked at something called gamma delta T cells. And T cells are really important. They're part of the anti-tumor response. They're what the body uses to attack the tumor. So we like those T cells. And particularly, these gamma delta T cells are important in targeting tumor cells in glioblastoma cells. They're also unique. They can avoid the toxicity of chemotherapy. Radiation therapy and chemotherapy suppresses the T cells. They make some go down, or decreased in number, which is not what we want. And these gamma delta T cells were genetically created so that they were resistant to chemotherapy. And that's really, really important. We want an immunotherapy that works and one that isn't suppressed by our other treatments. And that's been a real barrier for glioma patients. So in this phase 1 study, they found the right dose of these gamma delta T cells, and that's the goal of a phase 1 study. But there were some early signs that this may be changing the tumor. One of the patients underwent surgery before and after they got this infusion. And we were able to see this. Investigators were able to see the gamma delta T cells up in the tumor. So this doesn't change practice. Patients don't need to go out and seek out the gamma delta T cells yet. But it's one of those early findings that says that we need to keep looking at immunotherapy. And as a community, this is something we need to keep focusing on. And then the last abstract and study I wanted to focus on is for a rare disease. This would not be something that would be relevant for all of our listeners and the brain tumor patients but for a subgroup of patients that have a condition called VHL, or von Hippel-Lindau. And von Hippel-Lindau is a genetic condition. So, most brain tumors are not inherited. You don't get it from a mom or a dad or pass it on, except for these patients, you do. And it comes from a gene that's inherited in families called the VHL or the von Hippel-Lindau gene. And these patients are predisposed to get tumors all throughout the body and the kidneys and the brain and the eye. And this is a lifelong disease where these tumors can really grow slowly over time and cause significant problems. And in the past few years, there's been a new treatment called belzutifan. Belzutifan is the name of this drug that has been shown to be effective in the kidney tumors for patients with VHL. And at ASCO this year, there was a new study showing that it's also effective in treating the brain tumors for these patients. And that's really important. We just haven't had a treatment other than surgery or radiation therapy for these tumors. And oftentimes, they grow after surgery and radiation therapy and we need an additional treatment. So in this study, the investigators looked at, "Does this drug belzutifan work for treating the CNS tumors, hemangioblastoma?" And found that around 50% of patients had a response, so a shrinkage in the size of the tumor. 90% of patients had control of their brain tumor disease, which is really important. And it worked really quickly, so it worked in about 3 to 5 months, which is shorter than what we would see for the kidney tumors. So that's exciting news for VHL patients, patients with von Hippel-Lindau, and another important update from the 2023 ASCO. So thanks for listening to this update of CNS brain tumors at the 2023 ASCO Annual Meeting. Again, I'm Roy Strowd, a neuro-oncologist at Wake Forest University School of Medicine. Delighted to bring you this brief summary of new research in the field. ASCO: Thank you, Dr. Strowd. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Dr. Alessandro Sette is a Center Head, Division Head, and Professor at the La Jolla Institute of Allergy and Immunology. His lab focuses on understanding the immune response, measuring immune activity, and developing disease intervention strategies against cancer, autoimmunity, allergy, and infectious diseases. He talks about bringing a biotech mindset back to academia, cross-reactive T cell responses to SARS-CoV-2, and compiling an immune-epitope database.

This week on Conversations on Dance, we are happy to bring you a chat with our friend, Damien Johnson. The topic of today's conversation was suggested by one of our listeners who was looking for us to delve into male specific training and some of the issues that arise that are different from females in the field. Damien is a permanent guest faculty member at The School of American Ballet, and a sought after teacher who is certified in the American Ballet Theatre National Training Curriculum in Pre-Primary-Level 3 as well as classical Pilates through Power Pilates. It was just announced that Damien will be stepping into the role of Upper Division Head at The Washington School of Ballet after his recent time as a faculty at Central Pennsylvania Youth Ballet.Damien is the perfect person to chat with about this topic as he shares advice for young male dancers navigating an aspiring career in ballet.Special thanks to Brett Elizabeth Gardner for this topic suggestion. As a parent of a male dancer, who is now a part of a second company, Brett has founded The Ballet Help Desk, to help other parents support their dancers as they navigate the serious ballet training path. The Ballet Help Desk provides an extensive digital library, featuring a collection of articles and videos. Users can explore various topics, ranging from the path to becoming a professional dancer to how to choose a ballet residential program to how ballet competitions fit into the mix. Be sure the check them out at ballethelpdesk.com.LINKS:Website: conversationsondancepod.comInstagram: @conversationsondanceMerch: https://bit.ly/cod-merchYouTube: https://bit.ly/youtube-CODJoin our email list: https://bit.ly/mail-COD Hosted on Acast. See acast.com/privacy for more information.

In our last episode, we spoke with negotiations expert and founder of the Center for Leadership, Dr. Cheri Hobgood, about the art of a good negotiation. This week, we've partnered with Women in PEM again to explore how negotiations can play out in the real world of emergency medicine. Dr. Selena Hariharan returns to share her personal experience and Dr. Elizabeth Alpern offers some concrete advice on how to prepare for an interview, read a contract, and make the outcome of the negotiation beneficial to all parties. It's all about time, money, and power! Was this series helpful to you? Have you been able to put some of these strategies into practice? We'd love to know! Tag us on social media, @empulsepodcast, or reach out via email empulsepodcast@gmail.com, or through our website, ucdavisem.com. Please encourage your friends and colleagues to listen and share their stories, too! ***Please rate us and leave us a review on iTunes! It helps us reach more people.*** Hosts: Dr. Julia Magaña, Associate Professor of Pediatric Emergency Medicine at UC Davis Dr. Sarah Medeiros, Associate Professor of Emergency Medicine at UC Davis Guests: Dr. Elizabeth Alpern, Professor of Pediatrics, Division Head of Emergency Medicine, and Associate Chair for Faculty Development Dr. Selena Hariharan, Women in PEM Co-Chair and Professor of Pediatrics Division of Pediatric Emergency Medicine at Cincinnati Children's Hospital Resources: Women in PEM SoMe: @womeninpem Email: womeninpem@gmail.com Center for Leadership Life Barrick L, Bechtel K, Cooper G, Hall JE, Levine DA, Reichard KG, Reed J, White ML, Langhan ML. Building the Foundation: A Call to Action for Baseline Data. Pediatr Emerg Care. 2023 Apr 1;39(4):294-295. doi: 10.1097/PEC.0000000000002902. Epub 2023 Jan 8. PMID: 36625447. Chumpitazi CE, Allister L, Cho C, Hoffmann JA, Hsu D, Iyer M, Mangold K, Marino M, Randell KA, Ponce H, Hariharan S. Career Development in Pediatric Emergency Medicine: What Do We Need? Pediatr Emerg Care. 2022 Sep 1;38(9):e1552-e1556. doi: 10.1097/PEC.0000000000002720. Epub 2022 Apr 28. PMID: 35470318; PMCID: PMC9912171.  *** Thank you to the UC Davis Department of Emergency Medicine for supporting this podcast and to Orlando Magaña at OM Productions for audio production services.

The inaugural holder of the Robert R. Rosenheim Endowed Chair for Nephrology at Connecticut Children's. Dr. Mason, who serves as the Division Head for Nephrology, is the first woman of the African diaspora and first woman of Jamaican heritage to hold an endowed chair at Connecticut Children's

Dr. Stuart Berger, Division Head of Cardiology at Lurie Children's Hospital, joins Lisa Dent to talk about why he started Project ADAM and why it’s important for people to know how to respond to sudden cardiac arrest, whether it happens during a sporting event or in a classroom. Follow The Lisa Dent Show on Twitter:Follow […]

Dr. Robert O'Toole, Professor of Orthopaedic Trauma, Division Head of Orthopaedic Traumatology, Chief of Orthopaedics at the R Adams Cowley Shock Trauma Center, Program Director of the Orthopaedic Traumatology Fellowship Program, Department of Orthopaedics at the University of Maryland Medical Center discusses the recent METRC study comparing aspirin vs LMWH for DVT prophylaxis in ortho […]

Mark D. Miller, MD, retired Colonel in the US Airforce, S. Ward Casscells Professor, former Division Head of Sports Medicine at University of Virginia, and AOSSM President, shares how he published 40 textbooks and started a review course, his role as Deputy Editor of Journal of Bone and Joint Surgery, his leadership role at AOSSM, and more. 

Following the evacuation of Boston in March of 1776, London authorities knew that Britain's small British alone could not possibly conquer the American continent.  King George III, also the Elector of Hanover, reached out to his German relations and other allied provinces to provide auxiliary forces to send to America.  Arriving first at New York in 1776, about 30,000 German soldiers would serve in the American War for Independence.  Friederike Baer, Associate Professor & Division Head of the Arts & Sciences at Pennsylvania State University's Abington College, joins us to talk about their experiences, which she tells in her new book Hessians:  German Soldiers in the American Revolutionary War, the first comprehensive account of the German experience in the American war.

What is it like to go to camp when it's nothing like the world you know? What's it like to move from camper to counselor and then to Division Head? How do we apply the lessons of camp back home? Jorge Perez is kind enough sit around the campfire and answer these and many other questions. Enjoy!

Artificial Intelligence is being used to enhance the diagnosis tools used by radiologists.  We talk with Georgia Spear, MD, Division Head of Breast Imaging at NorthShore University HealthSystem about the latest screening tools, the future of radiology, and what you need to know when you get your mammogram. Georgia Spear, MD, speaks about the past, present and future of breast cancer screening including her efforts to create new laws to help women with dense breast tissue get the right screening.  She is board certified in Diagnostic Radiology and works at NorthShore University HealthSystem. To learn more about NorthShore's Breast program, including info about the Automated Whole Breast Ultrasound (ABUS), go to www.northshore.org/mammogram/ or call 888-364-6400 for scheduling.Produced by Jon Hillenbrand and Carolyn Starks.  Edited by Jon Hillenbrand.

Dr. Chris Keefer teamed up with Dr. Douglas Boreham, Professor and Division Head of Medical Sciences at the Northern Ontario School of Medicine, to speak before residents in South Bruce, Ontario, the potential site of Canada's Deep Geological Repository for used nuclear fuel. The event, organized by the local grassroots group Willing to Listen, features presentations from each speaker followed by an open Q&A session. Recorded Sept. 17, 2022. **DECOUPLE READS** We are excited to launch Decouple Reads with Brahm Neufeld!! Join us on Patreon for virtual book club meetings on selected books from the Decouple library: https://www.patreon.com/decouple Listen to Brahm's first appearance and book review on Decouple: https://www.decouplemedia.org/podcast/episode/36d91df3/decouple-reads-fossil-futureclimate-change-as-class-war **** Learn more about Willing to Listen: https://www.willingtolisten.ca/ Learn more about the Deep Geological Repository project from nuclear operator Sheila Whytock, an organizer for Willing to Listen, on the We CANDU It podcast: https://anchor.fm/wecanduit/episodes/Deep-Geologic-Repository--Willing-to-Listen-feat-Sheila-Whytock-eqo293/a-a4n6q4k Listen to Douglas Boreham's appearances on Decouple: https://www.decouplemedia.org/podcast/episode/4916a9ed/how-radiation-affects-us-feat-dr-douglas-boreham https://www.decouplemedia.org/podcast/episode/3cc88d07/testing-the-credibility-of-linear-no-threshold

Welcome to Protecting Your Nest with Dr. Tony Hampton. Dr. Diana Bottari is the Division Head of Pediatric Sedation and Medical Director of Pediatric Pain at Advocate Children's Hospital. She went to Medical School at Chicago College of Osteopathic Medicine and completed her residency at Advocate Children's Hospital where she now works. In this discussion, Drs. Tony and Diana talk about: (03:49) Dr. Diana's medical background and how she became interested in holistic care (15:06) The difference between functional medicine and integrated medicine (23:24) The differences between practicing integrated medicine and standard medicine (31:07) Progress in the treatment of chronic pain (36:56) The treatment modalities Dr. Diana utilizes in her practice as an integrative medicine physician (45:32) Motivational interviewing and empowering patients with knowledge and understanding (47:39) Creative and inexpensive solutions to patient pain (54:42) General protocols for healthy living (58:39) Future visions for health care reform Thank you for listening to Protecting Your Nest. For additional resources and information, please see the links below.    Links:   Dr. Diana Bottari: Advocate Health Care Profile Linkedin   Dr. Tony Hampton: Linktree Instagram Account LinkedIn Account Ritmos Negros Podcast